Thomas Taapken joined Imcyse in 2019 as Chairman of the Board after the successful completion of a Series B financing to manage the Company’s transition period and reorganize the management team. Thomas is an independent adviser with over 25 years of experience in the life sciences sector at senior management and board levels. Prior to joining Imcyse, he held executive management positions at several private and publicly listed companies, including Medigene AG, Epigenomics AG and Biotie Therapies Oyj. He has also served on the board of private and public companies such as Scibase AB, Immunic AG and others. He has successfully completed public and private financings, business and M&A transactions and worked in venture capital in both Germany and the U.S. Thomas holds a Ph.D. in Organic Chemistry from the Technical University of Berlin. He also studied economics and physics at the University of Göttingen.
Christina Franssen joined the Board of Imcyse in 2019. She is Investment Manager – Life Sciences Innovation at S.R.I.W. (Société Régionale d’Investissement de Wallonie). Christina has over 15 years’ experience in innovation and research. Prior to being appointed to her current position, she was business development Manager and then Director of state-of-the-art technology platforms at GIGA (University of Liège). Christina began her career as a research scientist at the University of Liège, where she experienced a full cycle of entrepreneurship from the founding of a spin-off company to its exit. Christina holds a Master degree in Biology and a Ph.D. in Genetics from the University of Liège.
Jörg Neermann joined the Board of Imcyse in 2019. He joined LSP as Partner in 2007 as Partner. Jörg’s prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, he was the Managing Director of Deutsche Bank’s DVC, where he ran its Healthcare Investment Franchise. Previously, Jörg worked at Atlas Ventures in Germany where he also invested in the healthcare sector. He has been appointed a director at a large number of companies, all of which he has supported with his scientific expertise, biotechnology experience and global networks. Jörg holds a Master’s degree and a Ph.D. in Biotechnology from the Technical University in Braunschweig and Massachusetts Institute of Technology in Cambridge, U.S. He also studied economics at Harvard Business School in Boston, U.S.
Stijn Van Rompay joined the Board of Imcyse in 2012. He is an investor with over 20 years’ experience in the private equity and life sciences sectors at senior management and board levels. Stijn co-founded and was CEO of Alter Pharma, a high-growth pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.
Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.
Hughes Wallemacq joined the Board of Imcyse in 2020. He has been an Investment Manager at Noshaq since 2020. Hugues has broad experience in the medical field ranging from research and development to commercialization of innovative vaccines and diagnostic applications. He is experienced in innovation within the biotech and pharmaceutical industries. Hugues has served at executive management and board positions for several companies including GSK Vaccines, Unisensor, Osivax, MagniSense and PDC*Line. He is a Doctor of Veterinary Medicine and holds a Ph.D. in Immunology from the University of Liège.
Stefan Yee joined the Board of Imcyse in 2019. He has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance, investment banking and private equity in companies such as KPMG, Linklaters, The Flemish investment bank Lessius, the Belgian Corporation for International Investment (SBI/BMI), Beluga (Euronext Brussels) and as the founder and CEO of the PE Group, a Belgian privately held private equity firm. Stefan is, and has been an investor and/or board member of several listed and private companies such as, amongst others, Beluga, Encare group (Mensura), AXI, The Reference, Alro Holdings, Loomans Group, United Brands, Capco, Faseas International (Spacewell), HD Partners (Dekabo group), AED Rent, UnifiedPost Group, NRG New Generation, Axiles Bionics, including, besides Imcyse, several healthcare companies (Docpharma (formerly Euronext Brussels), Uteron Pharma and Hyloris Pharmaceuticals). Stefan holds a Master’s degrees in Law and Business Management from the Universities of Brussels (VUB and ULB Solvay Business School) and the University of Chicago (as BAEF Fellow).
ImCyse is supported by the Walloon region, the European 7th Framework program and by Life Science Research Partners (LSRP).